Johnson & Johnson vs Merck & Company at a glance
Both companies operate in the Health Care sector, so these figures are broadly like-for-like.
| Metric | JNJ | MRK |
|---|---|---|
| Market cap | $654.04B | $366.72B |
| Price | $268.04 | $148.35 |
| P/E ratio (TTM) | 18.74 | 14.18 |
| P/B ratio (MRQ) | 6.16 | 4.92 |
| P/S ratio (TTM) | 5.33 | 3.98 |
| Revenue growth (1Y) | 6.05% | 1.31% |
| Return on equity (TTM) | 32.87% | 34.70% |
| Return on invested capital (TTM) | 16.26% | 22.71% |
| Gross margin (TTM) | 75.17% | 82.44% |
| Net margin (TTM) | 21.48% | 13.59% |
| Dividend yield (TTM) | 2.00% | 2.29% |
How they differ
Johnson & Johnson is the larger company at $654.04B versus $366.72B — about 1.8x the size.
On trailing earnings, Merck & Company is the cheaper of the two at 14.18 against 18.74 for Johnson & Johnson.
On sales, Merck & Company is the cheaper of the two at 3.98 against 5.33 for Johnson & Johnson.
Johnson & Johnson leads on revenue growth over the past year, 6.05% against 1.31%.
Merck & Company leads on return on invested capital, 22.71% against 16.26%.
Merck & Company leads on gross margin, 82.44% against 75.17%.
Merck & Company offers the higher yield at 2.29% against 2.00%.
Go deeper
Ratios describe the past. Whether either is worth owning depends on what you pay today.
Related comparisons
Other matchups involving Johnson & Johnson or Merck & Company.